
EquitySector - HealthcareVery High Risk
NAV (27-Aug-26)
Returns (Since Inception)
Fund Size
₹14 Cr
Expense Ratio
0.14%
ISIN
INF769K01QA6
Minimum SIP
-
Exit Load
-
Inception Date
11 Feb 2026
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+18.18%
— (Cat Avg.)
| Equity | ₹13.97 Cr | 99.81% |
| Others | ₹0.03 Cr | 0.19% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹1.41 Cr | 10.06% |
| Divi's Laboratories Ltd | Equity | ₹1.03 Cr | 7.36% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹0.93 Cr | 6.63% |
| Cipla Ltd | Equity | ₹0.83 Cr | 5.96% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹0.82 Cr | 5.88% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.76 Cr | 5.40% |
| Laurus Labs Ltd | Equity | ₹0.71 Cr | 5.08% |
| Dr Reddy's Laboratories Ltd | Equity | ₹0.7 Cr | 5.03% |
| Lupin Ltd | Equity | ₹0.59 Cr | 4.22% |
| Fortis Healthcare Ltd | Equity | ₹0.5 Cr | 3.54% |
| Aurobindo Pharma Ltd | Equity | ₹0.44 Cr | 3.14% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.34 Cr | 2.42% |
| Alkem Laboratories Ltd | Equity | ₹0.34 Cr | 2.42% |
| Biocon Ltd | Equity | ₹0.31 Cr | 2.18% |
| Zydus Lifesciences Ltd | Equity | ₹0.28 Cr | 2.03% |
| Mankind Pharma Ltd | Equity | ₹0.28 Cr | 2.01% |
| Ipca Laboratories Ltd | Equity | ₹0.24 Cr | 1.74% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.21 Cr | 1.50% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹0.21 Cr | 1.50% |
| Gland Pharma Ltd | Equity | ₹0.2 Cr | 1.43% |
| Sai Life Sciences Ltd | Equity | ₹0.18 Cr | 1.30% |
| Neuland Laboratories Ltd | Equity | ₹0.16 Cr | 1.17% |
| Wockhardt Ltd | Equity | ₹0.16 Cr | 1.16% |
| Acutaas Chemicals Ltd | Equity | ₹0.16 Cr | 1.16% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.15 Cr | 1.07% |
| Ajanta Pharma Ltd | Equity | ₹0.15 Cr | 1.05% |
| Abbott India Ltd | Equity | ₹0.14 Cr | 1.03% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.14 Cr | 1.01% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.13 Cr | 0.92% |
| Piramal Pharma Ltd | Equity | ₹0.12 Cr | 0.87% |
| Global Health Ltd | Equity | ₹0.12 Cr | 0.86% |
| Granules India Ltd | Equity | ₹0.12 Cr | 0.86% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.11 Cr | 0.79% |
| Natco Pharma Ltd | Equity | ₹0.08 Cr | 0.59% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.08 Cr | 0.55% |
| Jubilant Pharmova Ltd | Equity | ₹0.08 Cr | 0.54% |
| Syngene International Ltd | Equity | ₹0.07 Cr | 0.53% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.07 Cr | 0.53% |
| Pfizer Ltd | Equity | ₹0.07 Cr | 0.52% |
| Anthem Biosciences Ltd | Equity | ₹0.07 Cr | 0.52% |
| Cohance Lifesciences Ltd | Equity | ₹0.07 Cr | 0.50% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.07 Cr | 0.48% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.07 Cr | 0.47% |
| Poly Medicure Ltd | Equity | ₹0.07 Cr | 0.47% |
| Indegene Ltd | Equity | ₹0.05 Cr | 0.38% |
| Caplin Point Laboratories Ltd | Equity | ₹0.05 Cr | 0.36% |
| Concord Biotech Ltd | Equity | ₹0.05 Cr | 0.34% |
| Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.23% |
| Net Receivables / (Payables) | Cash | ₹0.02 Cr | 0.16% |
| Treps | Cash - Repurchase Agreement | ₹0 Cr | 0.03% |
Large Cap Stocks
35.42%
Mid Cap Stocks
45.59%
Small Cap Stocks
18.80%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹13.81 Cr | 98.66% |
| Basic Materials | ₹0.16 Cr | 1.16% |
Standard Deviation
This fund
--
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.90
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.55
Higher the better

Since February 2026
Since February 2026
ISIN INF769K01QA6 | Expense Ratio 0.14% | Exit Load - | Fund Size ₹14 Cr | Age 6 months | Lumpsum Minimum - | Fund Status Open Ended Investment Company | Benchmark Nifty 500 Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,31,587 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments